Does Aetna (CVS Health) Cover Finasteride?

How Aetna Classifies Finasteride on Its Formulary

Generic finasteride appears on the vast majority of Aetna commercial plan formularies at Tier 1 or Tier 2, but the tier alone does not determine your out-of-pocket cost. Aetna administers dozens of distinct plan designs under its CVS Health umbrella, and the specific tier assignment in your Evidence of Coverage document controls your copay. Finasteride 5 mg for benign prostatic hyperplasia tends to land at Tier 1 more reliably than finasteride 1 mg for androgenetic alopecia, which some plans classify as a cosmetic or lifestyle drug and either exclude entirely or place at Tier 3.

Finasteride 1 mg (brand name Propecia) received FDA approval for male-pattern hair loss in 1997 [1]. The drug's mechanism, 5-alpha-reductase type II inhibition, reduces scalp dihydrotestosterone by approximately 60%, which is the basis for both its hair and prostate indications [2]. Kaufman et al. (J Am Acad Dermatol 1998, N=1,553) demonstrated that finasteride 1 mg produced statistically significant increases in hair count versus placebo at 12 months (P<0.001), with 83% of treated men maintaining or increasing hair count at two years [3].

Because that same clinical evidence base supports the drug's cosmetic use, Aetna's medical policy teams frequently categorize the 1 mg dose differently from the 5 mg dose even though both are off-patent generics. Always pull your specific plan's drug list from the Aetna website or call the pharmacy benefits number on your insurance card before assuming tier status.

The finasteride 5 mg formulation for BPH carries stronger clinical support for coverage. The PLESS trial (N=3,040) showed finasteride 5 mg reduced the risk of acute urinary retention by 57% and the need for BPH-related surgery by 55% over four years (P<0.001) [4]. Insurers recognize that outcome, and prior authorization for the 5 mg BPH indication is less common than for the 1 mg hair loss indication.

Prior Authorization Criteria Aetna Uses for Finasteride

Prior authorization for finasteride is most common for the androgenetic alopecia indication and applies less consistently to BPH. For hair loss, Aetna's PA criteria typically require documentation of the diagnosis, the prescriber's specialty or clinical notes confirming male-pattern hair loss (Hamilton-Norwood scale stage II or higher), and in many plans, evidence that the member has tried or cannot tolerate topical minoxidil first.

For BPH, PA may be triggered if the 5 mg dose is written by a non-urologist, if the member has not yet had a documented prostate symptom score assessment (AUA Symptom Score), or if the plan suspects the prescription is actually for off-label hair loss use. American Urological Association guidelines recommend finasteride as a standard medical therapy for men with prostate volumes above 30 mL [5], and submitting that guideline reference with a PA request strengthens the clinical rationale.

PA requests are submitted by your prescribing physician, not by you directly. The typical timeline under federal law is 72 hours for standard PA and 24 hours for urgent requests. Aetna's own published turnaround standard for pharmacy PA is 24 to 72 hours for non-urgent cases. If the PA is denied, that denial must come with a written reason, which you will need for the appeal.

The HealthRX clinical team reviewed Aetna PA submission patterns across its telehealth patient cohort and identified three documentation elements that most reliably prevent first-pass denials: (1) a photograph or validated hair-count scale result attached to the PA request, (2) a note from the prescriber explicitly referencing the AUA or American Academy of Dermatology guidelines, and (3) a statement that the member has no contraindication to minoxidil but has already tried it for at least 16 weeks without adequate response.

Step Therapy Requirements Before Finasteride Approval

Step therapy for finasteride means Aetna may require you to try a cheaper or preferred drug first before it will authorize finasteride. For the hair loss indication, the most common step-therapy predecessor is topical minoxidil 5% solution or foam, sold over the counter under brand names Rogaine and Kirkland Signature. Minoxidil does not require a prescription, costs roughly $15 to $30 per month, and Aetna can document your purchase history through CVS Pharmacy records if you use the CVS ExtraCare card.

The clinical rationale for step therapy in this context is debatable. A 2019 systematic review in JAMA Dermatology found that combining finasteride and minoxidil produced superior hair counts compared with either agent alone [6]. That evidence arguably supports using both drugs together rather than sequentially, and a prescriber who cites this literature in the PA submission may successfully avoid step therapy by framing finasteride as a complementary rather than a replacement therapy.

For BPH, step therapy predecessors may include alpha-blockers such as tamsulosin (Flomax) or terazosin. The FDA-approved labeling for finasteride 5 mg notes that combination therapy with an alpha-blocker (specifically doxazosin in the MTOPS trial, N=3,047) reduced the risk of BPH clinical progression by 66% compared with placebo [7]. Citing combination therapy guidelines from the AUA can sometimes reframe finasteride as a necessary add-on rather than a second-line alternative, which sidesteps the step-therapy requirement.

If your plan imposes step therapy and you believe it is clinically inappropriate for your situation, your physician can submit a step-therapy exception request alongside the standard PA form. Most states now have laws that require insurers to grant exceptions within 72 hours when a physician certifies that the required first-step drug is contraindicated, has already failed, or is not clinically appropriate.

What Finasteride Costs With and Without Aetna Coverage

The brand-name finasteride product Propecia (1 mg) carries a list price near $85 per month. Generic finasteride 1 mg from major manufacturers typically runs $12 to $20 per month at retail pharmacy cash-pay prices, including at CVS Pharmacy. Generic finasteride 5 mg costs slightly less per pill and, because it can be split into quarters, some men prescribed 1 mg use the 5 mg tablet at about $3 to $5 per month out of pocket, though that practice should be discussed with a physician.

With Aetna coverage at Tier 1, your copay may fall between $0 and $15 per 30-day supply. At Tier 2, expect $20 to $45. At Tier 3, copays can reach $50 to $80, at which point cash-pay generic pricing is cheaper for most people. The FDA approved the first generic finasteride in 1997 under ANDA processes [8], and competition among generics has kept cash prices low ever since.

Manufacturer savings cards for Propecia brand are generally unusable with federal or state insurance programs, and Aetna's commercial plans contractually prohibit applying third-party coupons to covered claims in most plan designs. However, if Aetna does not cover a particular finasteride dose or indication, that prescription becomes an out-of-network or non-covered item, at which point you are free to use GoodRx, a manufacturer card, or any other discount tool. Telehealth platforms that prescribe finasteride directly often use compounding pharmacies or cash-pay dispensing to achieve sub-$20 monthly prices without insurance involvement at all.

How to Appeal an Aetna Finasteride Denial

An Aetna denial for finasteride is not the end of the road. Federal law under the Affordable Care Act and the Employee Retirement Income Security Act (ERISA) gives you the right to at least one internal appeal and, in most cases, an external independent review.

Step one is a first-level internal appeal. You have 180 days from the denial date to file. Your physician should submit a letter of medical necessity that directly addresses the reason Aetna cited for the denial. If the denial was based on the drug being cosmetic, cite the clinical evidence: Kaufman et al. (1998) showed finasteride 1 mg maintained hair count in 83% of participants versus 28% in the placebo group at two years [3]. If the denial was for failure to meet step-therapy requirements, document the minoxidil trial dates, the response, and any adverse effects.

Step two is a second-level internal appeal, available in some plans, which goes to a different Aetna reviewer than the first denial.

Step three is external independent review, administered by an independent review organization (IRO) contracted by your state insurance commissioner. The IRO's decision is binding on Aetna in most states. National external review data compiled by the Kaiser Family Foundation show that consumers win roughly 40% of external reviews for prescription drug denials across major insurers [9].

Step four, if needed, is a complaint to your state insurance commissioner or, for ERISA-governed employer plans, a complaint to the U.S. Department of Labor. Filing a commissioner complaint sometimes triggers a faster voluntary resolution from Aetna before formal regulatory action.

Keep every piece of paperwork. Date-stamp your submissions. Send appeals by certified mail or through the Aetna member portal with a confirmation screenshot.

BPH vs. Androgenetic Alopecia: Why the Indication Changes Everything

Aetna's coverage calculus differs sharply between these two indications because one is classified as a medical condition and the other is often classified as cosmetic. BPH is a progressive disease: left untreated, it carries a measurable risk of acute urinary retention, recurrent urinary tract infections, and bladder damage [10]. Finasteride's effect on those hard endpoints, demonstrated in the PLESS trial [4], makes it difficult for a medical director to justify a denial based on cost alone.

Androgenetic alopecia does not carry the same acute medical risk profile. Most Aetna medical policy documents that exclude or restrict finasteride for hair loss cite the cosmetic classification explicitly. The American Academy of Dermatology's clinical guideline on androgenetic alopecia recommends finasteride as a first-line pharmacologic option for men [11], and that guideline reference is worth including in every PA submission and appeal letter for this indication.

One nuance: if a physician documents that a patient's hair loss is causing clinically significant psychological distress, some reviewers will reclassify the condition as a mental health-related medical necessity. This framing requires careful documentation in the clinical notes and should be discussed with the prescriber.

How Generic vs. Brand Name Affects Aetna Authorization

Aetna will almost never authorize brand-name Propecia when generic finasteride is available, and for good reason: the active ingredient, dose, and bioavailability are identical. The FDA's generic drug approval process requires demonstration of bioequivalence, typically within a 90% confidence interval of 80% to 125% for the 90% CI of AUC and Cmax [12]. Generic finasteride meets this standard.

If your prescription is written for brand-name Propecia, the pharmacy will likely dispense generic automatically under Aetna's mandatory generic substitution rules. If your physician writes "dispense as written" for a brand reason, Aetna may cover the drug at the generic copay and require you to pay the brand price difference, which can be substantial.

There is no clinical reason to prefer brand Propecia over generic finasteride for most patients. The 5 mg tablet used off-label as a pill-splitter for 1.25 mg dosing is a separate discussion, but the 1 mg generic remains the standard pharmacologically equivalent substitute.

Telehealth and Compounding: The Alternative When Aetna Denies Coverage

When Aetna denies finasteride and appeal efforts are unsuccessful, two practical alternatives exist. First, cash-pay generic finasteride at CVS or another retail pharmacy costs $12 to $20 per month without insurance. For a medication with no clinical difference between branded and generic versions, the cash-pay route eliminates PA paperwork entirely.

Second, some telehealth platforms prescribe compounded finasteride or finasteride-plus-minoxidil topical solutions dispensed directly from 503A compounding pharmacies. Compounded drugs are not FDA-approved products [13], which matters for safety monitoring, but the active pharmaceutical ingredient is the same. Compounded finasteride topical solutions deliver lower systemic exposure than oral tablets, which may be relevant for patients concerned about systemic side effects including sexual dysfunction, which the FDA label identifies as occurring in approximately 1.4% of men taking finasteride 1 mg in clinical trials [1].

The prescribing physician should weigh these options with the patient. For BPH specifically, oral finasteride 5 mg remains the clinically validated route, and compounded alternatives have no large-scale trial data supporting efficacy on hard urological endpoints.

The 5-Alpha-Reductase Inhibitor Category and Related Dutasteride Coverage

Finasteride is one of two 5-alpha-reductase inhibitors on the U.S. market. Dutasteride (Avodart) inhibits both type I and type II isoenzymes and reduces serum DHT by approximately 90% versus finasteride's 65 to 70% [14]. Some Aetna plans prefer dutasteride for BPH because it is available as a low-cost generic and may offer modestly greater symptom relief in men with larger prostates.

If Aetna denies finasteride 5 mg for BPH, asking the prescriber whether dutasteride is clinically equivalent for the individual patient is worth exploring. If dutasteride is on Aetna's preferred drug list and your physician agrees it is appropriate, switching may be faster than appealing.

For androgenetic alopecia, dutasteride is not FDA-approved in the U.S. (though it is approved for that indication in South Korea and Japan [15]). Aetna will almost certainly deny dutasteride for hair loss as an off-label use, with less clinical justification available for appeal than exists for finasteride.